Dr. Lal Pathlabs Limited · NSE:LALPATHLAB
Dr. Lal Pathlabs — Investor Presentation (May 2017)
27 slides from Dr. Lal Pathlabs's investor presentation, May 2017
Slide 1: Dr. Lal PathLabs Limited Corporate Presentation
Dr. Lal PathLabs Limited Corporate Presentation May 2017
Slide 2: Table of Contents
2 Table of Contents 1 Our Evolution 2 Dr Lal PathLabs at a glance 3 Experienced Management team 4 Investment Highlights 5 Key Q4 & FY17 Highlights 6 Q4 & FY17 Financial Performance 7 LPL Strategy for future growth 8 Annexures DISCLAIMER: This presentation may contain ‘forward-looking’ statements at
Slide 3: Our Evolution
3 Our Evolution 1949 – 2005 2005 – 2010 2010 – 2017 Foundation Building capabilities for Strong position in North scale up India, building network in other geographies 1949: Founded by Dr. Major S. 2005: onwards: Investment Investment by TA Associates K. Lal by WestBridge Capital Clinical la
Slide 4: Dr. Lal PathLabs at a glance
4 Dr. Lal PathLabs at a glance Test Menu Established consumer healthcare brand in diagnostic services Specialized Routine testing testing Pan-India integrated coverage with 189 clinical labs (including National Reference Lab1 at Delhi),1,759 Patient Bio-chemistry Molecular Service Centers (PSCs)
Slide 5: Experienced Management team
Experienced Management team (Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Whole-time Director and Chief Chairman and Managing Director Whole-time Director Executive Officer Dilip Bidani Bharath Uppiliappan Shankha Banerjee Chief Financial Officer COO (Strategic Business Unit 1) COO –
Slide 6: Investment Highlights
6 Investment Highlights Well-positioned in one of Scalable model integrated Established consumer the fastest-growing through centralized IT healthcare brand in segments of the Indian platform allows for diagnostic services healthcare industry network expansion Attractive operating Robust financial m
Slide 7: Indian Healthcare Services is a large growth opportunity
7 Indian Healthcare Services is a large growth opportunity 1.42 bn India’s expected population in 2026 India, highly underpenetrated market 7.6% GDP growth in FY161 INR 4.2 trillion Total Healthcare Expenditure as % of GDP (2013) FY14 India healthcare expenditure 17.1% ~68% Private expenditure on he
Slide 8: Growth Drivers
8 INR 377 bn Diagnostic Services industry expected to grow to INR 600 bn by FY18 Diagnostic Services Industry Size CAGR: INR 600 bn Growth Drivers 16–17% 1 Increase in evidence-based INR 377 bn treatments 2 Demand for lifestyle diseases- related services to grow 2014–15 2017–18P 3 Focus on preventiv
Slide 9: Diagnostic Services industry remains highly fragmented
9 Diagnostic Services industry remains highly fragmented Highly Fragmented Industry Standalone Centres, 48% Large Pan- India Chains 35-40% Diagnostic Regional Chain, 15% Chains 60- 65% Hospital Based, 37% Largely fragmented and unorganized Source: CRISIL Report titled “Assessment of Diagnostics Indu
Slide 10: Pillars of a Strong Brand
10 Established consumer healthcare brand in Diagnostic Services Pillars of a Strong Brand Accreditations Nationwide Network Fast Turnaround Time Accreditations from CAP, Coverage in metros, Tier 1 24x7 access including online NABL and ISO and Tier 2 cities access and home collection Centrall
Slide 11: Hub and Spoke Model Network Expansion
11 Scalable Model integrated through centralized IT platform allows for network expansion Hub and Spoke Model Network Expansion PSC PSC No. of Clinical No. of PSCs No. of PUPs Reference Laboratories Lab Clinical Clinical 5,668 Lab Lab 1,759 189 5,021 4,967 1,559 172 164 4,225 1,340 146 PSC PSC PSC P
Slide 12: Integrated National Network backed by Centralized IT platform
12 Scalable Model integrated through centralized IT platform allows for network expansion Integrated National …backed by Centralized IT platform Network… which fully integrated network Enterprise Resource Payables, receivables, inventory, ledgers etc. Planning (ERP) Scalability and connectivity
Slide 13: Collection network
13 Collection network LPL’s scalable business model provides strategic advantage for expansion and consolidation National Reference Lab Clinical Labs (Testing/Collection) Patient Service Centers Pickup Points Home Walk-ins Collection Hospitals Doctors Labs Walk-ins Diverse, large customer pool W
Slide 14: Attractive operating metrics
14 Attractive operating metrics No. of patients No. of samples Total Revenue (Mn) (Mn) (INR mn) Higher revenue realization per Consumer brand and network patient on account of: Increase in samples with patient expansion driving patient Growth in walk-in customers volumes growth volumes Hig
Slide 15: Multiple levers in place to drive next phase of growth
15 Multiple levers in place to drive next phase of growth Expand through Expand presence in Focus on hospital- strategic acquisitions existing markets based clinical labs and partnerships Cluster and focused geography approach Deepen presence in North M&A provides growth kicker Increase exis
Slide 16: Strategies to deepen our presence
16 Strategies to deepen our presence South and North India East India West India Focus on Preventive healthcare retail Commitment to quality Online report; screening and chronic network and and reliability of data analytics / lifestyle disease home services management services collection Provide bot
Slide 17: Robust financial performance
17 Robust financial performance Total Revenue Revenue by Geography (FY17) EBITDA1,PAT and Return on Net Worth INR (Mn) (%) (INR mn / %) EBITDA Margin West India, Others, Before ESOP 27.6% 27.3% 26.7% 27.0% 7.6% 1.2% charge1 South India, 6.7% PAT Margin 14.4% 14.6% 16.8% 17.0% RONW 40.8% 33.7% 31.4%
Slide 18: Robust financial performance (Cont'd)
18 Robust financial performance (Cont’d) Fixed Asset Turnover1 Cash and Cash Equivalents (Times) (INR mn) 4,000 3882 3.6x 3,500 3.4x 3.3x 3.3x 2945 3,000 1046 2,500 643 2,000 1861 1,500 379 1143 2,836 86 1,000 2,302 1,482 500 1,057 0 FY14 FY15 FY16 FY17 FY14 FY15 FY16 FY17 Cash and Bank Current Bala
Slide 19: Key Q4 & FY17 Highlights
19 Key Q4 & FY17 Highlights Growth is gradually normalising post demonetisation with volume trajectory showing improvement QoQ During Q4 FY17 : Revenues showed 11.3% increase at Rs. 2199 million with underlying volume growth of 7.7% in Q4 Normalised EBITDA (after eliminating the impact of ES
Slide 20: Q4 & FY17 Financial Performance
20 Q4 & FY17 Financial Performance Particulars (Rs. mn) Q4 FY17 Q4FY16 Growth % FY17 FY16 Growth % Revenues 2,199.0 1,977.1 11.2% 9,123.8 7,913.2 15.3% Total Expenditure 1,705.5 1,435.8 18.8% 6,758.4 5,816.0 16.2% EBITDA 493.5 541.3 (8.8)% 2365.4 2097.2 12.8% ESOP/ ESPS/ RSU charges 26.0 (15.4) - 80
Slide 21: Financial Highlights
21 Financial Highlights Revenues All figures in Rs mn 2,622 9,124 2,228 2,199 2,075 7,913 1,977 Q4FY16 Q1FY17 Q2FY17 Q3FY17 Q4FY17 FY16 FY17 Q4 FY17 revenues reported 11.3% growth on the back of expansion in volumes by 7.7% YoY. Improvement in business momentum QoQ indicates: Increased footprint
Slide 22: Financial Highlights
22 Financial Highlights All figures in Rs mn Normalised EBITDA excl stock based cost and CSR expense During Q4FY17 the growth in normalised 529 538 EBITDA (after eliminating the impact of stock 2,465 based cost and CSR expenses) stood moderated 2,110 at 1.8% on account of; Higher investments in
Slide 23: LPL Strategy for future growth
23 LPL Strategy for future growth 1 Strengthen Existing Operations Boosting quality & Improving Grow basic Online initiatives Investment in reliability turnaround times radiology practice and data analytics branding standards for testing 2 Expansion in Offering Improve breadth Preventive Chronic & L
Slide 24: Annexures
Annexures • IPO transaction • Present Shareholding
Slide 25: IPO transaction
25 IPO transaction Issuer Dr. Lal PathLabs Limited (“LPL” or “the Company”) Transaction Type Initial public offering of up to 11,600,000 shares (Face Value Rs.10 each) Issue Open and Close Dates December 8, 2015 – December 10, 2015 Type of Offering Offer for Sale by existing shareholders Tot
Slide 26: Shareholding as on March 31, 2017
26 Shareholding as on March 31, 2017 58.2% Promoters 1.9% MFs FPIs & FIIs FI/Banks 6.0% Other Public Employee Trust 23.5% 10.0% 0.42%
Slide 27: Contact us
27 Contact us About Dr Lal PathLabs Limited (DLPL) Dr Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests